2-(4-甲氧基苯基)-1,3-噻唑-4-羧酸 | 57677-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-甲氧基苯基)-1,3-噻唑-4-羧酸
• 中文别名: 2-(4-甲氧基苯基)噻唑-4-羧酸；2-(4-甲氧苯基)-1,3-噻吩-4-甲酸
• 英文名称: 2-(4-methoxyphenyl)thiazole-4-carboxylic acid
• 英文别名: 2-(4-methoxyphenyl)-1,3-thiazole-4-carboxylic Acid
• CAS: 57677-80-2
• 化学式: C₁₁H₉NO₃S
• mdl: MFCD03791177
• 分子量: 235.263
• InChiKey: OIBLFOXWCGIRIQ-UHFFFAOYSA-N

物化性质

• 熔点：
  176-178°C
• 沸点：
  449.7±51.0 °C(Predicted)
• 密度：
  1.352±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934100090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-(4-Methoxyphenyl)-1,3-thiazole-4-carboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-(4-Methoxyphenyl)-1,3-thiazole-4-carboxylic acid
Ingredient name:
CAS number: 57677-80-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H9NO3S
Molecular weight: 235.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-甲氧基苯基)-1,3-噻唑-4-羧酸 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 1-[2-(4-甲氧基-苯基)-噻唑-4-基]-乙酮
  参考文献：
  名称：

  Rh(iii)-catalyzed cyclization reaction of azoles with alkynes: efficient synthesis of azole-fused-pyridines

  摘要：

  已开发出一种Rh（III）催化的氮杂环与炔烃的环化反应，可在良好至优异的产率下构建杂环并联吡啶。

  DOI：

  10.1039/c5ob01338k
• 作为产物：
  描述：

  4-甲氧基硫代苯甲胺 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 2-(4-甲氧基苯基)-1,3-噻唑-4-羧酸
  参考文献：
  名称：

  一种1-(2-(4-甲氧基苯基)噻唑-4-基)乙胺及其合成方法

  摘要：

  本发明属于有机合成技术领域，公开了一种1‑(2‑(4‑甲氧基苯基)噻唑‑4‑基)乙胺及其化学合成方法。所述方法为：以4‑甲氧基苯甲酸为原料，经酰化、取代、磺酰化、取代、水解、取代、取代、及还原反应九步反应制备了1‑(2‑(4‑甲氧基苯基)噻唑‑4‑基)乙胺。为该化合物的合成提供了一种高效合成的方法。

  公开号：

  CN111848545B

文献信息

• Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics
  作者：Waleed M. Hussein、Daniel Feder、Gerhard Schenk、Luke W. Guddat、Ross P. McGeary

  DOI：10.1016/j.ejmech.2018.08.004

  日期：2018.9

  obtaining the human enzyme, the corresponding enzymes from red kidney bean and pig have been used previously to develop specific PAP inhibitors. Here, existing lead compounds were further elaborated to create a series of inhibitors with Ki values as low as ∼30 μM. The inhibition constants of these compounds were of comparable magnitude for pig and red kidney bean PAPs, indicating that relevant binding interactions

  紫色酸性磷酸酶（PAP）是在酸性条件下催化磷酸酯水解的金属酶。它们的活性位点在哺乳动物中包含Fe（III）Fe（II）金属中心，而在植物中包含Fe（III）Zn（II）或Fe（III）Mn（II）金属中心。在人类中，血清中PAP水平升高与骨质疏松症和代谢性骨恶性肿瘤的进展密切相关，这使PAP成为适合开发化学疗法以对抗骨疾病的靶标。由于难以获得人的酶，红芸豆和猪的相应酶以前已被用于开发特定的PAP抑制剂。在这里，对现有的先导化合物进行进一步的精制，以创建一系列具有K i的抑制剂。值低至约30μM。这些化合物对猪和红芸豆PAP的抑制常数具有可比的大小，表明相关的结合相互作用得以保留。与该系列中最有效的抑制剂化合物4f配合使用时，红芸豆PAP的晶体结构解析为2.40Å的分辨率。根据其竞争性抑制方式，该抑制剂可直接与活性位点的双核金属中心配位。对接模拟预测该化合物以相似的方式与人PAP结合。该研究
• Synthesis, characterization, crystal structure and urease-inhibition activities of three 2-phenylthiazole derivatives
  作者：Da-Hua Shi、Xiao-Dong Ma、Zong-Ming Tang、Tong Dong、Bao-Yun Xu、Yu-Wei Liu、Xiao-Kai Song、Wei-Wei Liu、Meng-Qiu Song

  DOI：10.1016/j.molstruc.2018.06.096

  日期：2018.12

  Abstract Three 2-phenylthiazole derivatives were synthesized, characterized and evaluated as urease inhibitors. The structures of the 2-phenylthiazole derivatives were characterized by FT-IR, 1H NMR and 13C NMR spectroscopy. Their crystal structures were also determined by single-crystal X-ray diffraction studies. Hirshfeld surfaces analysis and their associated two dimensional fingerprint plots of

  摘要 合成、表征和评价了三种 2-苯基噻唑衍生物作为脲酶抑制剂。2-苯基噻唑衍生物的结构通过FT-IR、1H NMR和13C NMR光谱表征。它们的晶体结构也通过单晶 X 射线衍射研究确定。Hirshfeld 表面分析及其相关的化合物二维指纹图被用作理论方法，通过合成化合物的晶格中的分子间相互作用评估晶体结构形成的驱动力。所制备化合物的X射线单晶衍射和Hirshfeld表面分析研究表明合成化合物分子之间存在NH⋯O氢键和CH⋯O分子间相互作用。采用酚红法测定合成化合物的脲酶抑制活性。在三种化合物中，化合物N-环己基-2-(4-甲氧基苯基)噻唑-4-甲酰胺(5b)表现出最好的脲酶抑制活性，IC50为1.82 μM。对接研究表明，化合物N-环己基-2-(4-甲氧基苯基)噻唑-4-甲酰胺可以与脲酶的催化活性位点相互作用。
• Synthesis, Crystal Structure and Biological Evaluation of Novel 2-Phenylthiazole Derivatives as Butyrylcholinesterase Inhibitors
  作者：Da-Hua Shi、Xiao-Dong Ma、Yu-Wei Liu、Wei Min、Fu-Jun Yin、Zong-Ming Tang、Meng-Qiu Song、Chen Lu、Xiao-Kai Song、Wei-Wei Liu、Tong Dong

  DOI：10.3184/174751918x15314837408346

  日期：2018.7

  To find novel butyrylcholinesterase inhibitors, three novel 2-phenylthiazole derivatives were synthesised. The synthesised compounds were characterised by NMR and single-crystal X-ray diffraction analysis. Hirshfeld surface analysis and two-dimensional fingerprint plots of the compounds were used as a theoretical approach to assess the driving force for crystal structure formation via the intermolecular

  为了找到新型丁酰胆碱酯酶抑制剂，合成了三种新型 2-苯基噻唑衍生物。合成的化合物通过核磁共振和单晶X射线衍射分析进行表征。Hirshfeld 表面分析和化合物的二维指纹图被用作一种理论方法，通过合成化合物的晶格中的分子间相互作用来评估晶体结构形成的驱动力。在这三种化合物中，N-(1,5-二甲基-3-氧代-2-苯基-2,3-二氢-1H-吡唑-4-基)-2-(4-甲氧基苯基)噻唑-4-甲酰胺表现出最好的丁酰胆碱酯酶抑制活性，IC50 值为 75.12 μM。对接研究表明，该化合物与丁酰胆碱酯酶的外周阴离子位点相互作用。
• FAP 저해제로서의 피롤리딘 유도체 및 이를 포함하는 약학적 조성물
  申请人：Boryung Corporation 주식회사 보령(119980015994) Corp. No ▼ 110111-0012560BRN ▼208-81-00281

  公开号：KR20200115934A

  公开（公告）日：2020-10-08

  본 발명은 FAP 저해제로서 하기 화학식 X로 나타내는, 피롤리딘 유도체 또는 그의 약학적으로 허용되는 염을 포함한다. [화학식 X]

  本发明涉及一种FAP抑制剂，包括用化学式X表示的吡啶衍生物或其药学上可接受的盐。 [化学式 X]
• NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160311833A1

  公开（公告）日：2016-10-27

  The present application relates to novel 6-substituted indazoles having a carboxamide side chain, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of endometriosis, lymphomas, macular degeneration, COPD and psoriasis.

  本申请涉及具有羧酰胺侧链的新型6-取代吲唑的化合物，以及它们的制备方法，单独或组合用于治疗和/或预防疾病，以及用于制备用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防子宫内膜异位症、淋巴瘤、黄斑变性、慢性阻塞性肺病和牛皮癣。